HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency.

Abstract
Factor XI deficiency, an injury-related bleeding disorder, is rare worldwide but common in Jews in whom 2 mutations, Glu117Stop (type II) and Phe283Leu (type III), prevail. Mean factor XI activities in homozygotes for Glu117Stop and for Phe283Leu are 1 and 10 U/dL, respectively. Inhibitors to factor XI in patients with severe factor XI deficiency have been reported in a small number of instances. This study was undertaken to determine the prevalence of acquired inhibitors against factor XI in patients with severe factor XI deficiency, discern whether these inhibitors are related to specific mutations, and characterize their activity. Clinical information was obtained from unrelated patients with severe factor XI deficiency, and blood was analyzed for factor XI activity, inhibitor to factor XI, and causative mutations. Immunoglobulin G purified from patients with an inhibitory activity was tested for binding to factor XI, effects on activation of factor XI by factor XIIa and thrombin, and activation of factor IX by exogenous factor XIa. Of 118 Israeli patients, 7 had an inhibitor; all belonged to a subgroup of 21 homozygotes for Glu117Stop who had a history of plasma replacement therapy. Three additional patients with inhibitors from the United Kingdom and the United States also had this genotype and were exposed to plasma. The inhibitors affected factor XI activation by thrombin or factor XIIa, and activation of factor IX by factor XIa. The results imply that patients with a very low factor XI level are susceptible to development of an inhibitor following plasma replacement.
AuthorsOphira Salomon, Ariella Zivelin, Tami Livnat, Rima Dardik, Ron Loewenthal, Ophelia Avishai, David M Steinberg, Michael H Rosove, Niamh O'Connell, Christine A Lee, Uri Seligsohn
JournalBlood (Blood) Vol. 101 Issue 12 Pg. 4783-8 (Jun 15 2003) ISSN: 0006-4971 [Print] United States
PMID12586617 (Publication Type: Journal Article)
Chemical References
  • Autoantibodies
  • Histocompatibility Antigens Class II
  • Immunoglobulin G
  • Recombinant Proteins
  • Factor IX
  • Factor XI
  • Factor VIIa
  • Factor XIa
  • Factor XIIa
  • Thrombin
Topics
  • Aged
  • Autoantibodies (blood)
  • Factor IX (metabolism)
  • Factor VIIa (pharmacology)
  • Factor XI (immunology, metabolism)
  • Factor XI Deficiency (epidemiology, etiology, genetics, immunology)
  • Factor XIIa (pharmacology)
  • Factor XIa (pharmacology)
  • Female
  • Genotype
  • Histocompatibility Antigens Class II (genetics)
  • Humans
  • Immunoglobulin G (blood)
  • Israel
  • Jews
  • Male
  • Middle Aged
  • Mutation
  • Partial Thromboplastin Time
  • Plasma
  • Recombinant Proteins (pharmacology)
  • Thrombin (metabolism, pharmacology)
  • United Kingdom
  • United States

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: